ReviewInternational journal of molecular sciences2020
Hematological Diseases and Osteoporosis.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- New Insights Into Pathophysiology of β-Thalassemia.Frontiers in medicine · 2022Pooled it
- Osteoporosis After Menopause and After Drug Therapy: The Molecular Mechanism of Bone Loss and Its Treatment.International journal of molecular sciences · 2026Review
- Bone mineral density assessment by DXA in disease-associated osteoporosis: the limitations.Frontiers in endocrinology · 2026Review
- Macrophage iron overload promotes osteoporosis via Cxcl3- and Cxcl7-mediated paracrine signaling in ovariectomized mice.Journal of orthopaedic translation · 2026Article
- Musculoskeletal manifestations of sickle cell disease: an imaging perspective.Skeletal radiology · 2025Review
- Green Tea Extract Containing Epigallocatechin-3-Gallate Facilitates Bone Formation and Mineralization by Alleviating Iron-Overload-Induced Oxidative Stress in Human Osteoblast-like (MG-63) Cells.Antioxidants (Basel, Switzerland) · 2025Article
- Evaluation of Vitamin D and of Some Biomarkers of Bone Remodelling (CTX-1, Osteocalcin, BALP) in Subjects with Periapical Inflammatory Cysts: An Observational Study.Journal of clinical medicine · 2025Article
- Trabecular bone score in the assessment of bone health in thalassemia major.Frontiers in endocrinology · 2025Article
- Reference intervals for hematology, serum biochemistry and blood gas parameters in Indian elephants (Frontiers in veterinary science · 2025Article
- Perioperative risk factors for osteoporosis after radical gastrectomy for gastric cancer.BMC surgery · 2024Article
- Article
- Abnormally low serum albumin levels are associated with abnormal bone mineral density and osteoporotic fractures: a retrospective studies.BMC musculoskeletal disorders · 2024Article
- Quantitative detection of macular microvascular abnormalities identified by optical coherence tomography angiography in different hematological diseases.Scientific reports · 2024Article
- Osteoporosis in Systemic Mastocytosis: A Scoping Review.Medicina (Kaunas, Lithuania) · 2024Article
- Pre-Transplant Dual-Energy X-ray Absorptiometry (DXA)-Derived Body Composition Measures as Predictors of Treatment Outcomes and Early Post-Transplant Complications in Patients with Multiple Myeloma (MM) Treated with Autologous Hematopoietic Stem Cell Transplantation (AutoHSCT).Journal of clinical medicine · 2024Article
- Clinical significance of FLC tests in patients without other evidence of hematologic disorder.Clinical and experimental medicine · 2024Article
- Article
- Bone Health Impairment in Patients with Hemoglobinopathies: From Biological Bases to New Possible Therapeutic Strategies.International journal of molecular sciences · 2024Review
- Osteoporosis treatment: current drugs and future developments.Frontiers in pharmacology · 2024Review
- Haemophilia and Fragility Fractures: From Pathogenesis to Multidisciplinary Approach.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Secondary osteoporosis is a common clinical problem faced by bone specialists, with a higher frequency in men than in women. One of several causes of secondary osteoporosis is hematological disease. There are numerous hematological diseases that can have a deleterious impact on bone health. In the literature, there is an abundance of evidence of bone involvement in patients affected by multiple myeloma, systemic mastocytosis, thalassemia, and hemophilia; some skeletal disorders are also reported in sickle cell disease. Recently, monoclonal gammopathy of undetermined significance appears to increase fracture risk, predominantly in male subjects. The pathogenetic mechanisms responsible for these bone loss effects have not yet been completely clarified. Many soluble factors, in particular cytokines that regulate bone metabolism, appear to play an important role. An integrated approach to these hematological diseases, with the help of a bone specialist, could reduce the bone fracture rate and improve the quality of life of these patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.